Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Adalimumab × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1 Dermatologic 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

Everolimus 13 Magnetic Resonance Spectroscopy 7 lutetium Lu 177 dotatate 6 Cisplatin 5 gallium Ga 68 dotatate 4 Specimen Handling 4 Nivolumab 4 Fluorodeoxyglucose F18 4 pasireotide 3 Positron Emission Tomography Computed Tomography 3 Etoposide 3 Carboplatin 3 (177)Lu-DOTA-EB-TATE 3 pembrolizumab 2 olaparib 2 dabrafenib 2 amino-acid, glucose, and electrolyte solution 2 Trastuzumab 2 Radiotherapy 2 Radiation 2 Photochemotherapy 2 Paclitaxel 2 Octreotide 2 Lutetium-177 2 Ipilimumab 2 Iodine-131 2 Ga(III)-DOTATOC 2 FAPI-46 2 Doxorubicin 2 Cyclophosphamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02516774 2016-01-26

TAM-RT

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Withdrawn

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡